<table>
<thead>
<tr>
<th>Title</th>
<th>SMA Screening System Using Dried Blood Spots on Filter Paper: Application of COP-PCR to the SMN1 Deletion Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Kato, Nozomu / Sa'adah, Nihayatus / Rochmah, Mawaddah Ar / Harahap, Nur Imma Fatimah / Nurputra, Dian Kesumapramudya / Sato, Hideyuki / Sadewa, Ahmad Hamim / Astuti, Indwiani / Haryana, Sofia Mubarika / Saito, Toshio / Saito, Kayoko / Nishimura, Noriyuki</td>
</tr>
<tr>
<td>Citation</td>
<td>The Kobe journal of the medical sciences, 60(4):78-85</td>
</tr>
<tr>
<td>Issue date</td>
<td>2014</td>
</tr>
<tr>
<td>Resource Type</td>
<td>Departmental Bulletin Paper / 紀要論文</td>
</tr>
<tr>
<td>Resource Version</td>
<td>publisher</td>
</tr>
<tr>
<td>DOI</td>
<td></td>
</tr>
<tr>
<td>JaLCDOI</td>
<td>10.24546/81008730</td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://www.lib.kobe-u.ac.jp/handle_kernel/81008730">http://www.lib.kobe-u.ac.jp/handle_kernel/81008730</a></td>
</tr>
</tbody>
</table>

PDF issue: 2018-11-01
SMA Screening System Using Dried Blood Spots on Filter Paper: Application of COP-PCR to the SMN1 Deletion Test

NOZOMU KATO1,2, NIHAYATUS SA’ADAH1,3, MAWADDAH AR ROCHMAH1, NUR IMMA FATIMAH HARAHAP1, DIAN KESUMAPRAMUDYA NURPUTRA1, HIDEYUKI SATO1, AHMAD HAMIM SADEWA3,4, INDWIANI ASTUTI3,5, SOFIA MUBARIKA HARYANA3,6, TOSHIO SAITO7, KAYOKO SAITO8, NORIYUKI NISHIMURA1, HISAHIKI NISHIO1 and ATSUKO TAKEUCHI2*

1 Department of Community Medicine and Social Healthcare Science, Kobe University Graduate School of Medicine, Kobe, Japan; 2 Kobe Pharmaceutical University, Kobe, Japan; 3 Basic Medical and Biomedical Sciences, Graduate School of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia; 4 Department of Biochemistry, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia; 5 Department of Pharmacology, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia; 6 Department of Histology and Cell Biology, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia; 7 Division of Child Neurology, Department of Neurology, National Hospital Organization Toneyama National Hospital, Toneyama, Japan; 8 Institute of Medical Genetics, Tokyo Women’s Medical University, Tokyo, Japan

Keywords: spinal muscular atrophy, SMN1, SMN2, COP-PCR, dried blood spot

BACKGROUND: Spinal muscular atrophy (SMA) is a common neuromuscular disorder caused by mutations in SMN1. More than 95% of SMA patients carry homozygous SMN1 deletions. Thus, the SMN1 deletion test should be performed initially as part of the diagnostic process. However, SMN2, a highly homologous gene, hampers detection of SMN1 deletion. To differentiate between SMN1 and SMN2, many analysis methods have been developed yet they are not all available worldwide. AIM: To establish a simple but accurate SMN1-deletion detection system that can be used worldwide. METHODS: Fifty DNA samples (29 SMA patients and 21 controls) from dried blood spots (DBS) on filter paper were assayed. All participants had previously been screened for SMA by PCR-restriction fragment length polymorphism (PCR-RFLP) using DNA extracted from freshly collected blood. DNA was extracted from DBS that had been stored at room temperature (20–25°C) for between 1 and 8 years. Competitive oligonucleotide priming-PCR (COP-PCR) was performed to distinguish SMN1 and SMN2 exon7. RESULTS: DNA yield from an 11-mm diameter DBS circle was 21,171 ± 7,485 ng (mean ± SD), with an 260/280 OD ratio from 1.49 to 2.1 (mean ± SD: 1.67 ±0.13). Nucleotide sequencing confirmed gene-specific amplification of SMN1 and SMN2 by COP-PCR. SMN1 and SMN2 COP-PCR results are completely consistent with those obtained by PCR-RFLP. CONCLUSION: We have combined DNA extraction from DBS on filter paper with COP-PCR that specifically detects SMN1 and SMN2, establishing a new SMN1-deletion detection system with practical application worldwide.
INTRODUCTION

Spinal muscular atrophy (SMA) causes general muscle weakness because of a loss of lower motor neurons in the spinal cord. SMA is a common autosomal recessive disorder, with an incidence of 1/10,000 live births [24]. SMA is classified into three subtypes that depends on age of disease onset and achievement of motor milestones [19]: type 1 (severe form; onset age of 0–6 months, unable to sit unaided), type 2 (intermediate form; onset age of <18 months, unable to stand or walk unaided), and type 3 (mild form; onset age of >18 months, able to stand or walk unaided). Additionally, two other forms have been reported, SMA type 0 is the most severe and has a prenatal onset, while SMA type 4 is mildest and manifests after 20 years of age [12].

The gene for SMA, survival motor neuron 1 (SMN1), was cloned in 1995. SMN1 encodes the SMN protein, which plays a critical role in cellular metabolism [22]. More than 95% of SMA patients have homozygous SMN1 deletions [13], while the rest (< 5%) may carry intragenic SMN1 mutations or be non-SMN1-related SMA (non-5q-SMA) [13]. Thus, at the beginning of diagnosis, SMN1 deletion tests should be performed.

All SMA patients with homozygous SMN1 deletions carry at least one copy of the SMN2 gene, as complete loss of both SMN genes causes embryonic lethality [9, 27]. SMN2 is highly homologous to SMN1, with only five nucleotide differences between them [11], and SMN2 also produces a small amount of SMN protein [14]. The presence of SMN2 may compensate for loss of SMN1 to some degree, and higher copy numbers of SMN2 are correlated with milder SMA phenotypes [3,7,15,29,31]. However, with regard to diagnosis or screening by conventional PCR methods, SMN2 hampers detection of homozygous SMN1 deletion.

To address this problem, various unique PCR methods have been established, for example, PCR and single-strand conformation polymorphism (PCR-SSCP) [13], PCR and restriction fragment length polymorphism (PCR-RFLP) [30], radio-isotope competitive PCR [15], PCR and denaturing high-performance liquid chromatography (DHPLC) [28], real-time PCR [4], multiplex ligation probe amplification (MLPA) [1], tetra-primer PCR [2],and high-resolution melting analysis[18]. However, not one of these methods can be readily introduced into all laboratories, some require expensive equipment or special reagents (e.g. radioisotopes), while others require much effort and are time-consuming procedures. Thus, further research is needed for the innovation of new simpler methods for distinguishing between SMN1 and SMN2. We previously found that competitive oligonucleotide priming-PCR (COP-PCR) can separately amplify SMN1 and SMN2 [21], with each of the genes specifically amplified as usual by PCR.

In addition, when considering molecular analysis of any disease (including SMA), it should be noted that the capability to perform molecular analyses are not universally available in all geographical regions of the world. If simple method of collection, storage, and transfer of samples can be established, all patients will gain access to the benefits of molecular analysis regardless of geographical or industrial limitations [8]. We have previously reported that dried blood spots (DBS) on filter paper, which can be sent by mail, are a good DNA source for SMA diagnosis [8].

In this study, we combined DNA extraction from DBS on filter paper and COP-PCR analysis to establish a simple but accurate SMN1-deletion detection system that has practical utility in any area of the world. Here, we report on the yield and purity of DNA extracted from DBS, storage year effect on PCR amplification, and specificity of COP-PCR amplification.

MATERIAL AND METHODS

Patient and control samples

Fifty individuals were assayed, 28 SMA patients and 22 controls. All individuals had been previously analyzed by PCR-RFLP using DNA extracted from freshly collected blood [30]. Prior to analysis, informed consent was obtained from study participants. The study was approved by the Ethical Committee of Kobe University Graduate School of Medicine.

DNA extraction from DBS on filter paper

Blood samples were collected from SMA patients and controls using filter paper FTA® Elute Cards (Thermo Fisher Scientific, Waltham, MA, USA). Storage periods of blood samples on FTA® Elute Cards varied from 1 to 8 years. All FTA® Elute Cards were stored in the dark at room temperature (20–25°C). Genomic DNA was extracted from DBS according to our previous report [8]. Here, the protocol is briefly described. To extract DNA from DBS on cards, a hole punch was used to punch out seven 3-mm diameter circles from an 11-mm diameter DBS, equivalent to 50 µL of whole blood. The seven circles were placed into a sterile tube, washed in 500 µL distilled water, and vortexed three times. Washing water was completely removed from the circles, and 75 µL Tris-EDTA Buffer, pH 8.0 (TE buffer) added to the tube. The tube was heated at 95°C for 30 min, and then TE buffer containing DNA eluted and used as a DNA template for PCR or stored at ~20°C until use. The
concentration and absorbance ratio of the DNA solution were measured at 260/280 nm (260/280 OD ratio) using a NanoDrop® ND-1000 spectrophotometer (Thermo Fisher Scientific).

**COP-PCR for SMN1/SMN2 exon 7**

To separately amplify exon 7 from SMN1 and SMN2, we performed COP-PCR using a thermal cycler (Bio-Rad iCycler Thermal Cycler, Bio-Rad Laboratories, Inc., Foster City, CA, USA). The PCR mixture total volume was 30 µL, consisted of distilled water, genomic DNA template (50–500 ng), 10 pmol/µL of common forward primer (R111), 100 pmol/µL of gene-specific reverse primer (SMN1-COP or SMN2-COP), 10 mM dNTP, 10 × buffer with MgCl₂, and Taq DNA polymerase (Fast Start Taq DNA polymerase, Roche Applied Science, Mannheim, Germany). Primer sequences are shown in Fig. 1. After an initial denaturing step of 94°C for 7-min, 30 cycles were performed consisting of 1-min denaturing at 94°C, 1-min annealing at 35°C, and 1-min extension at 72°C, followed by 7-min at 72°C. An aliquot of each COP-PCR product was electrophoresed on a 4% agarose gel with 1×TBE buffer, and visualized by ethidium bromide staining.

**Sequencing of COP-PCR products**

Amplified COP-PCR products of SMN1/SMN2 exon 7 were purified and used for cycle sequencing reactions with R111 primer. Cycle sequencing products were directly sequenced using a dye terminator cycle-sequencing kit (Life Technologies Corporation, Carlsbad, CA, USA). Reaction products were electrophoresed on an ABI PRISM® 310 Genetic Analyzer (Life Technologies Corporation).

**RESULTS**

**Extracted DNA yield and storage period of DBS on filter paper**

The DNA yield in an 11-mm diameter DBS circle was 21,171 ± 7,485 ng (mean ± SD), with 260/280 OD ratio from 1.49 to 2.1 (mean ± SD; 1.67 ± 0.13) (Table I).

<table>
<thead>
<tr>
<th>DNA yield (ng) (11-mmØDBS circle)</th>
<th>DNA samples with good amplification (n=46)</th>
<th>DNA samples with no amplification (n=4)</th>
<th>All DNA samples (n=50)</th>
</tr>
</thead>
<tbody>
<tr>
<td>21,564 ± 7,268</td>
<td>16,650 ± 8,403</td>
<td>21,171 ± 7,485</td>
<td></td>
</tr>
<tr>
<td>1.68 ± 0.13</td>
<td>1.60 ± 0.06</td>
<td>1.67 ± 0.13</td>
<td></td>
</tr>
</tbody>
</table>

There were four DNA samples (three controls and one SMA patient) with no COP-PCR amplification of either gene. Non-amplification of both genes is considered a false result, as the combination of SMN1 and SMN2 deletion causes embryonic lethality [9,27]. To determine if these four samples were of sufficient quality for PCR, we performed a conventional PCR experiment using a primer set for the CFTR gene [15], which resulted in failure of CFTR fragment amplification (data not shown). Thus, we concluded that these four samples had deteriorated and were not suitable for PCR amplification, and therefore omitted them from further analysis.
These four DNA samples had been stored more than 4 years before analysis (Table II). Nevertheless, it should be noted that the DNA concentrations and 260/280 OD ratios of these samples were similar to those showing good amplification with SMN1-COP or SMN2-COP primers (Table I).

### Table II. Storage period of DBS on filter paper

<table>
<thead>
<tr>
<th>Years</th>
<th>0 - 1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Samples with amplification</td>
<td>8</td>
<td>6</td>
<td>7</td>
<td>4</td>
<td>9</td>
<td>7</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Samples with non-amplification</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
</tbody>
</table>

### COP-PCR amplification patterns

COP-PCR allowed us to separate \( SMN1 \) exon 7 from \( SMN2 \) exon 7 (Fig. 2). The COP-PCR diagnostic screening results are summarized in Fig. 3.

**Pattern 1**
(n=20)

\( SMN1 (+) / SMN2 (-) \)

**Pattern 2**
(n=3)

\( SMN1 (+) / SMN2 (-) \)

**Pattern 3**
(n=23)

\( SMN1 (-) / SMN2 (+) \)

In 18 controls and two patients with intragenic \( SMN1 \) mutations, COP-PCR using either R111 and SMN1-COP or R111 and SMN2-COP produced amplification products (Pattern 1 in Figs. 2 and 3). In three controls, COP-PCR using R111 and SMN1-COP produced an amplification product, while R111 and SMN2-COP produced no amplification product (Pattern 2 in Figs. 2 and 3). In 23 patients with homozygous \( SMN1 \) deletions, COP-PCR using R111 and SMN1-COP produced no amplification product, while R111 and SMN2-COP produced an amplification product (Pattern 3 in Figs. 2 and 3).

To confirm gene-specific amplification by COP-PCR, we performed nucleotide sequence analysis of COP-PCR products. According to a previous report [17], both \( SMN1 \) and \( SMN2 \) have gene-specific nucleotides in intron 6, with G and A nucleotides at position -44 from exon 7 of \( SMN1 \) and \( SMN2 \), respectively. As shown in Fig. 4, the COP-PCR product using R111 and SMN1-COP had a G nucleotide at position -44 from exon 7, while R111 and SMN2-COP had an A nucleotide. These findings show that COP-PCR can separately amplify \( SMN1 \) and \( SMN2 \) exon 7 in a gene-specific way.
COP-PCR with DBS-DNA vs. PCR-RFLP with DNA from freshly collected blood

COP-PCR results using DBS-DNA completely matched those of PCR-RFLP using DNA from freshly collected blood (Table III). COP-PCR results using R111 and SMN1-COP also completely matched those of PCR-RFLP (Table III A). Sensitivity and specificity of COP-PCR using DBS-DNA for SMN1 and SMN2 exon 7 were 100%. These results suggested that COP-PCR using DBS-DNA is useful for diagnostic screening of SMA patients.

Table III. Comparison between COP-PCR and PCR-RFLP

<table>
<thead>
<tr>
<th></th>
<th>PCR-RFLP (freshly collected blood)</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>COP-PCR (dried blood)</td>
<td>SMN1 Exon 7 Deletion</td>
<td>SMN1 Exon 7 Non-deletion</td>
</tr>
<tr>
<td>SMN1 Exon 7 Deletion</td>
<td>23</td>
<td>0</td>
</tr>
<tr>
<td>SMN1 Exon 7 Non-deletion</td>
<td>0</td>
<td>23</td>
</tr>
<tr>
<td>Total</td>
<td>23</td>
<td>23</td>
</tr>
</tbody>
</table>

Sensitivity 1.0, specificity 1.0

COP-PCR specificity confirmed by sequencing.

Nucleotide sequencing analysis confirmed SMN1- and SMN2-specific amplification. Nucleotide differences in intron 6 (*) and exon 7 (**) prove differential amplification of SMN1 and SMN2 by COP-PCR.

DISCUSSION

DBS on filter paper

In this study, we combined DNA extraction from DBS on filter paper with COP-PCR analysis of SMN1 and SMN2, establishing a simple but accurate SMN1-deletion detection system that has practical worldwide utility.

We used DBS-DNA as the PCR template, and obtained sufficient DNA for diagnosis of SMA. DBS on filter paper are practical and convenient with regard to handling (involves only spotting and drying blood on filter paper), transport (can be transferred by mail), storage (can be maintained at room temperature, and it is not necessary to store in a refrigerator), and cost (filter paper can be bought at minimal cost).
DBS have been used as biological specimens for more than 50 years, since Guthrie and Susi developed the phenylketonuria screening method to measure phenylalanine levels from DBS on filter paper [6]. Many technologies using DBS have already been developed and applied for medical purposes, including measurement of metabolites (e.g. adrenoleukodystrophy [20]), hormones (e.g. thyroid-stimulating hormone [11]), enzyme activities (e.g. glucose-6-phosphate dehydrogenase [26]), and drugs (e.g. antimalarial drugs [23]).

DBS are now recognized as a good source of DNA, and the combination of PCR with DNA from DBS enables genetic analysis [10, 16]. Molecular screening using DNA from DBS has already been reported for Duchenne/Becker muscular dystrophy and cystic fibrosis [25]. Our findings also support the use of DBS on filter paper as a good source of DNA for disease diagnosis. However, there are limitations to using DBS samples, and in particular, long-term storage of DBS cards may be associated with no PCR amplification, as in our study.

**COP-PCR**

We show here that COP-PCR can separately amplify the SMN genes, SMN1 and SMN2. COP-PCR is a type of allele-specific amplification, in which two oligonucleotide primers compete for DNA annealing. Competitive primers are shorter than usual PCR primers (which are typically 18–25 mer) and identical except for a nucleotide change that is located in the middle of the primer [5]. Amplification with the better-matched primer is favored 100-fold over the mismatched primer [5, 32]. Nucleotide sequencing confirmed that COP-PCR specifically amplified SMN1 and SMN2 exon 7. Comparison between COP-PCR and PCR-RFLP demonstrated a complete compatibility of both methods, proving the accuracy of COP-PCR. In addition, SMN1-deletion detection by COP-PCR is much faster than that by PCR-RFLP, because COP-PCR has no enzyme-digestion step. As to the required time from the start of PCR to the end of gel electrophoresis separating gene-specific products, COP-PCR takes only 3 hours, while PCR-RFLP takes more than 8 hours.

**Conclusion**

Here, we have combined DNA extraction from DBS on filter paper with COP-PCR that specifically detects SMN1 and SMN2, and established a new SMN1-deletion detection system that is practical for use even in remote areas of the world. Moreover, we also demonstrate that DBS on filter paper are a good source of DNA for disease diagnosis.

**DECLARATION OF INTEREST**

The authors declare that there is no conflict of interests regarding the publication of this paper.

**AUTHORS' CONTRIBUTION**

NOZOMU KATO and NIHAYATUS SA’ADAH contributed equally to this work.

**ACKNOWLEDGMENTS**

This study was supported in part by Grants-in-Aid provided by the Research Committee of Spinal Muscular Atrophy, and the Ministry of Education, Culture, Sports, Science and Technology of Japan (Project number 25860860)

**REFERENCES**


